Evaluation of glycopyrrolate and atropine as adjuncts to reversal of non-depolarizing neuromuscular blocking agents in a "true-to-life" situation.
Glycopyrrolate, a quaternary ammonium anticholinergic compound, and atropine were evaluated in combination with neostigmine for antagonism of non-depolarizing neuromuscular block. A total of 641 patients were investigated in a "true-to-life" situation. The patients receiving glycopyrrolate with neostigmine had smaller changes in heart rate than those who received atropine. This was particularly apparent in patients with cardiovascular disease.
D001285:Atropine / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006024:Glycopyrrolate / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000494:pharmacology; D009466:Neuromuscular Blocking Agents / Q000037:antagonists & inhibitors*; D009469:Neuromuscular Junction / Q000187:drug effects; D011759:Pyrrolidines / Q000494:pharmacology; D011897:Random Allocation; D013997:Time Factors
D009466:Neuromuscular Blocking Agents; D011759:Pyrrolidines; D009388:Neostigmine; D001285:Atropine; D006024:Glycopyrrolate